1. Home
  2. CGBD vs EVO Comparison

CGBD vs EVO Comparison

Compare CGBD & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Carlyle Secured Lending Inc.

CGBD

Carlyle Secured Lending Inc.

HOLD

Current Price

$11.55

Market Cap

826.2M

Sector

Finance

ML Signal

HOLD

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$3.00

Market Cap

934.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CGBD
EVO
Founded
2012
1993
Country
United States
Germany
Employees
2500
4553
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
826.2M
934.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CGBD
EVO
Price
$11.55
$3.00
Analyst Decision
Hold
Strong Buy
Analyst Count
8
1
Target Price
$12.92
$7.00
AVG Volume (30 Days)
858.7K
107.1K
Earning Date
05-11-2026
04-08-2026
Dividend Yield
14.54%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$3.74
$1.37
Revenue Next Year
$1.80
$10.05
P/E Ratio
$10.36
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.64
$2.31
52 Week High
$14.90
$4.80

Technical Indicators

Market Signals
Indicator
CGBD
EVO
Relative Strength Index (RSI) 53.42 51.88
Support Level $10.68 $2.87
Resistance Level $13.06 $3.78
Average True Range (ATR) 0.29 0.10
MACD 0.01 0.02
Stochastic Oscillator 65.49 50.00

Price Performance

Historical Comparison
CGBD
EVO

About CGBD Carlyle Secured Lending Inc.

Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Share on Social Networks: